Literature DB >> 8959327

Cell cycle-independent regulation of p21Waf1/Cip1 and retinoblastoma protein during okadaic acid-induced apoptosis is coupled with induction of Bax protein in human breast carcinoma cells.

M S Sheikh1, M Garcia, Q Zhan, Y Liu, A J Fornace.   

Abstract

Okadaic acid (OA) is a serine/threonine protein phosphatase inhibitor and has been shown to induce apoptosis in a number of different tumor cell lines, including human breast carcinoma (HBC) cells. The molecular basis of OA-induced apoptosis remains to be investigated. Here, we demonstrate that the OA concentration that inhibits only protein phosphatase 1 and 2A was sufficient to induce apoptosis in HBC cells. In MCF-7 cells, the OA-induced apoptosis was coupled with the overexpression of endogenous p53, p21Waf1/Cip1, and Bax proteins, whereas the Rb protein levels were decreased. OA also induced apoptosis and concomitantly enhanced the p21Waf1/Cip1 and Bex levels in human papilloma virus protein E6-transfected variants of MCF-7 cells, in which p53 function had been disrupted. OA, by contrast, had no effect on the levels or the subcellular localization of Gadd45 and Bcl2 proteins in either wild-type of E6-transfected MCF-7 cells. Bcl-xL, Bcl-xS, and Bak levels were also unchanged after OA treatment in both cell types. OA-induced apoptosis and its effect on the expression of the above molecular markers occurred in the absence of any detectable changes in the cell cycle phase distribution. On the basis of our findings, we conclude the following: (a) OA-induced apoptosis in HBC cells occurs independently of cell cycle arrest; (b) the wild-type p53 function is not an absolute prerequisite for OA-induced cell death; and (c) OA-induced apoptosis is associated with up-regulation of endogenous p21Waf1/Cip1 and Bax protein levels.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8959327

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  7 in total

1.  Recombinant deoxyribonucleoside kinase from Drosophila melanogaster can improve gemcitabine based combined gene/chemotherapy for targeting cancer cells.

Authors:  Mahak Fatima; Muhammad Mubashar Iqbal Ahmed; Faiza Batool; Anjum Riaz; Moazzam Ali; Birgitte Munch-Petersen; Zeeshan Mutahir
Journal:  Bosn J Basic Med Sci       Date:  2019-11-08       Impact factor: 3.363

2.  Antisense MDM2 enhances E2F1-induced apoptosis and the combination sensitizes androgen-sensitive [corrected] and androgen-insensitive [corrected] prostate cancer cells to radiation.

Authors:  Thirupandiyur S Udayakumar; Paul Hachem; Mansoor M Ahmed; Sudhir Agrawal; Alan Pollack
Journal:  Mol Cancer Res       Date:  2008-11       Impact factor: 5.852

3.  Interleukin-6 (IL-6) and IL-17 synergistically promote viral persistence by inhibiting cellular apoptosis and cytotoxic T cell function.

Authors:  Wanqiu Hou; Young-Hee Jin; Hyun Seok Kang; Byung S Kim
Journal:  J Virol       Date:  2014-05-14       Impact factor: 5.103

4.  Cribrostatin 6 induces death in cancer cells through a reactive oxygen species (ROS)-mediated mechanism.

Authors:  Mirth T Hoyt; Rahul Palchaudhuri; Paul J Hergenrother
Journal:  Invest New Drugs       Date:  2010-02-20       Impact factor: 3.850

5.  Ternary complex factor-serum response factor complex-regulated gene activity is required for cellular proliferation and inhibition of apoptotic cell death.

Authors:  Elaine R Vickers; Aneta Kasza; Isil Aksan Kurnaz; Anne Seifert; Leo A H Zeef; Amanda O'donnell; Andy Hayes; Andrew D Sharrocks
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

6.  Roles of the tumor suppressor p53 and the cyclin-dependent kinase inhibitor p21WAF1/CIP1 in receptor-mediated apoptosis of WEHI 231 B lymphoma cells.

Authors:  M Wu; R E Bellas; J Shen; G E Sonenshein
Journal:  J Exp Med       Date:  1998-05-18       Impact factor: 14.307

7.  Differentiation-induced radioresistance in muscle cells.

Authors:  Lucia Latella; Jiri Lukas; Cristiano Simone; Pier Lorenzo Puri; Jiri Bartek
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.